{
    "nct_id": "NCT04878003",
    "official_title": "An Open-Label, Multicenter, Phase 2 Study Assessing the Safety and Efficacy of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Na√Øve Myelofibrosis",
    "inclusion_criteria": "* Confirmed diagnosis of PMF, post-PV MF or post-ET MF (WHO)\n* High-risk, or intermediate-1 and 2 risk, defined by Dynamic International Prognostic System (DIPSS)\n* ECOG of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subjects who are positive for p53 mutation (Arm 1)\n* Prior MDM2 inhibitor therapy or p53-directed therapy (Arm 1)\n* Prior treatment with any JAK inhibitor\n* Prior splenectomy\n* Splenic irradiation within 24 weeks prior to randomization\n* Prior allogeneic stem-cell transplantation or plans for allogeneic stem-cell transplant\n* History of major organ transplant\n* Grade 2 or higher QTc prolongation\n* Major hemorrhage or intracranial hemorrhage within 24 weeks prior to randomization",
    "miscellaneous_criteria": ""
}